IPO registrations (S-1, F-1) · Registrants
Sana Biotechnology, Inc.
- SEC CIK
- 1770121 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-01-13, last 2021-02-03; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2021-02-05; declared effective 2021-02-03
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 188 EAST BLAINE STREET, SUITE 350, Seattle, WA
- EIN
- 83-1381173
- Ticker
- SANA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Sana Biotechnology, Inc. on the corporate pages
Offering terms
- Proposed price range
- $23.00–$24.00 per share (S-1/A filed 2021-02-03)
- Final price
- $25.00 per share, above the range (424B4 filed 2021-02-05, an initial public offering)
- Shares sold
- 23,500,000
- Gross proceeds
- $587,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SANA
- Lead underwriters
- Morgan Stanley; Goldman Sachs (6,345,000 shares); J.P. Morgan (6,345,000 shares); BofA Securities (4,465,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: SANA BIOTECHNOLOGY, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Sana Biotechnology, Inc Fuzzy (name and state)
- Business registration: Sana Biotechnology, Inc. Fuzzy (name and state)
- Business registration: Sana Biotechnology, Inc. Fuzzy (name and state)
- Business registration: SANA BIOTECHNOLOGY, INC. Fuzzy (name and state)
- Business registration: SANA BIOTECHNOLOGY, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: SANA BIOTECHNOLOGY, INC. EXACT (EIN (EXACT))
- Form D issuer: Sana Biotechnology, Inc. EXACT (CIK (EXACT))
- SEC filer: Sana Biotechnology, Inc. EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-01-13 | S-1 | S-1 (registration) | Sana Biotechnology, Inc. | 0001193125-21-007483 ↗ |
| 2021-01-28 | S-1/A | S-1/A (amendment) | Sana Biotechnology, Inc. | 0001193125-21-019984 ↗ |
| 2021-02-02 | S-1/A | S-1/A (amendment) | Sana Biotechnology, Inc. | 0001193125-21-025048 ↗ |
| 2021-02-03 | S-1/A | S-1/A (amendment) | Sana Biotechnology, Inc. | 0001193125-21-026330 ↗ |
| 2021-02-03 | S-1MEF | S-1MEF (added securities) | Sana Biotechnology, Inc. | 0001193125-21-027709 ↗ |
| 2021-02-03 | EFFECT | EFFECT (declared effective) | Sana Biotechnology, Inc. | 9999999995-21-000413 ↗ |
| 2021-02-05 | 424B4 | 424B4 (final prospectus) | Sana Biotechnology, Inc. | 0001193125-21-029606 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | S-1/A | registration statement | $23.00–$24.00 | 22,000,000 | - | Nasdaq SANA | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-02-05 | 424B4 | final prospectus | $25.00 | 23,500,000 | $587,500,000 | Nasdaq SANA | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AFEYAN NOUBAR | TenPercentOwner | 6 | 2021–2024 | ||
| AGARWAL SUNIL | Officer | EVP, Head of Development & CMO; See Remarks | 5 | 2021–2022 | |
| ARCH Venture Fund IX, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Fund IX Overage, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Fund X, L.P. | TenPercentOwner | 5 | 2021–2024 | ||
| ARCH Venture Fund X Overage, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Partners IX, LLC | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Partners IX Overage, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Partners X, LLC | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Partners X, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| ARCH Venture Partners X Overage, L.P. | TenPercentOwner | 3 | 2021–2024 | ||
| Bilenker Joshua H. | Director | 10 | 2021–2026 | ||
| Bishop Hans Edgar | Director | 28 | 2021–2026 | ||
| Burow Kristina | TenPercentOwner | 3 | 2021–2024 | ||
| BYBEE CLINTON | TenPercentOwner | 3 | 2021–2024 | ||
| Cole Douglas G. | Director | 7 | 2021–2024 | ||
| CRANDELL KEITH | TenPercentOwner | 3 | 2021–2024 | ||
| Flagship Pioneering Fund VI General Partner LLC | TenPercentOwner | 3 | 2021–2023 | ||
| Flagship Pioneering Fund VI, L.P. | TenPercentOwner | 3 | 2021–2023 | ||
| Flagship Pioneering Inc. | TenPercentOwner | 4 | 2021–2024 | ||
| Flagship VentureLabs V LLC | TenPercentOwner | 3 | 2021–2023 | ||
| Flagship VentureLabs V Manager LLC | TenPercentOwner | 3 | 2021–2023 | ||
| Flagship Ventures Fund V General Partner LLC | TenPercentOwner | 5 | 2021–2023 | ||
| Flagship Ventures Fund V, L.P. | TenPercentOwner | 5 | 2021–2023 | ||
| Flagship V VentureLabs Rx Fund, L.P. | TenPercentOwner | 5 | 2021–2023 | ||
| GILLIS STEVEN | TenPercentOwner | 3 | 2021–2024 | ||
| Hardy Nathan | Officer | EVP, Chief Financial Officer; SVP, Chief Financial Officer | 5 | 2021–2024 | |
| Harr Steve | Director,Officer | President & CEO | 9 | 2021–2026 | |
| Hordo Christian | Officer | EVP, Chief Business Officer; SVP, Chief Business Officer | 11 | 2021–2024 | |
| MacDonald James J. | Officer | EVP & General Counsel; See Remarks | 5 | 2021–2022 | |
| Mulligan Richard | Director; Director,Officer | Head of SanaX | 8 | 2021–2026 | |
| NELSEN ROBERT | Director; Director,TenPercentOwner | 16 | 2021–2026 | ||
| REICIN ALISE | Director | 9 | 2021–2026 | ||
| Seitz Michelle | Director | 9 | 2021–2026 | ||
| von Maltzahn Geoffrey | Director | 4 | 2021 | ||
| Wilderotter Mary Agnes | Director | 12 | 2021–2025 | ||
| Yang Patrick Y | Director | 11 | 2021–2026 | ||
| ARCH Venture Partners IX, L.P. | TenPercentOwner | 2 | 2021–2024 | ||
| Cassidy Bernard J | Officer | EVP & General Counsel | 6 | 2022–2025 | |
| WILLIAMS DOUGLAS E | Officer | EVP & President, R&D | 4 | 2023–2024 | |
| Flagship Pioneering Fund VII General Partner LLC | TenPercentOwner | 1 | 2024 | ||
| Flagship Pioneering Fund VII, L.P. | TenPercentOwner | 1 | 2024 | ||
| FMR LLC | TenPercentOwner,Other | 3 | 2024–2025 | ||
| Wyrick Susan D. | Officer | See Remarks | 10 | 2024–2026 | |
| Rosiello Robert L. | Director | 3 | 2025–2026 | ||
| Piper Brian | Officer | EVP, Chief Financial Officer | 2 | 2026 | |
| PATEL DHAVALKUMAR DHIRAJLAL | Officer | EVP, Chief Scientific Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-06-26 | Sana Biotechnology, Inc. | Biotechnology | $821,097,521 | $821,097,521 | 40 | 1 |
| 2020-06-26 | Sana Biotechnology, Inc. | Biotechnology | $45,850,000 | $45,850,000 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Sana Biotechnology, Inc | WA | State business registries | name and state |
| Business registration | Sana Biotechnology, Inc. | WA | State business registries | name and state |
| Business registration | Sana Biotechnology, Inc. | WA | State business registries | name and state |
| Business registration | SANA BIOTECHNOLOGY, INC. | WA | State business registries | name and state |
| Business registration | SANA BIOTECHNOLOGY, INC. | WA | State business registries | name and state |
| Business registration | SANA BIOTECHNOLOGY, INC. | WA | State business registries | name and state |
| Plan sponsor | SANA BIOTECHNOLOGY, INC. | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Sana Biotechnology, Inc. | WA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Sana Biotechnology, Inc. | WA | Patents (USPTO) | name and state |
| SEC filer | Sana Biotechnology, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Sana Biotechnology, Inc. | WA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | SANA BIOTECHNOLOGY, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), WA first:
- CORIXA CORP WA
- Seagen Inc. WA
- ZYMOGENETICS INC WA
- NS Wind Down Co., Inc. WA
- Adaptive Biotechnologies Corp WA
- Juno Therapeutics, Inc. WA
- LeonaBio, Inc. WA
- Icosavax, Inc. WA
- Intrinsic Medicine, Inc. WA
- Aurion Biotech, Inc. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health